Expert-Based Strategies to Improve Access to Cancer Therapeutics at the Hospital Level

Abstract

Background: Challenges related to access to cancer medications is an increasing global problem that has far-reaching impact on patients and healthcare systems. In this article, we are enlisting suggested solutions at the hospital or practice level to maximize the access to these important treatment modalities. Methods: An expert panel of practicing oncologists, clinical pharmacists, and health economists convened using a framework approach. The panelists identified individuals and entities that impact the use of cancer therapeutics and how they can improve the utilization and access to them. They enlisted the potential actions that hospital management and staff can take to enhance access to cancer therapeutics, then they grouped them into specific categories. Results: List of potential strategies and related action items were compiled into different categories including hospital leadership, drug evaluation entities, pharmacy, physicians, patients and families, and other parties. Recommendations included various actions to be considered by each group to achieve set goals. Conclusion: Our expert panel recommend multiple strategies and approaches to reduce the cost of cancer medications and improve patients' access to them. These recommendations can be adapted by the decision-makers and staff of the hospitals to their own settings and the current circumstances.

Lung Cancer in the Middle East and North Africa Region

“…There are multiple approaches to improve access to these medications that can be followed at national levels and at the hospital level. 20 Access to radiation therapy is limited in certain countries and regions. Existing centers have the potential to improve the techniques offered, such as stereotactic radiosurgery.…”

Implementation of Country-Wide Pharmacoeconomic Principles in Cancer Care in Developing Countries: Expert-Based Recommendations

“…This entity will monitor addition or deletion of medications and monitor the use to help ensure efficient use of resources. [21] 2. To create a working group to incorporate national guidelines into local practice evidence-and value-based protocols.…”

Pharmacoeconomic Trends, Applications, and Potential Developments

“…[8] In the foreseeable future, the economic burden of several diseases is likely to keep increasing-both in the case of infectious surges, like COVID-19, and chronic diseases, like cancer or diabetes-because of them being more prevalent and because of medications and other production factors becoming more expensive with time. [9] We will continue to witness impressive successes on the side of science with treatments and diagnostics, but these innovations will come at a cost. Irrespective of our healthcare systems and economies being able to bear those costs, we need sound methodology and data to make proper assessments and support decision making.…”